Highlights

  • Proteomics International scheduled national rollout of Promarker D and Promarker Eso.
  • Field sales teams completed test and access-process training.
  • The company scheduled collection and payment systems to go live on 26 October 2026.
  • The company targeted Promarker Endo commercial availability during Q3FY27.

Proteomics International Laboratories (ASX:PIQ) develops precision diagnostic tests and provides specialist bioanalytical services using protein-based technologies. Its 23 October 2026 update described preparations to widen Australian access to Promarker D and Promarker Eso. The move from a controlled regional release towards national distribution centred on trained staff, integrated collection processes and clinician education, with a third test planned for a later stage.

A Controlled Release Moves Towards National Access

National rollout was scheduled to commence on 26 October 2026 through the company's exclusive Australian pathology distribution partnership. It followed a controlled release in Western Australia and the Northern Territory announced in September.

The earlier phase provided operational experience before expanding availability across Australia. At the report date, the national launch remained scheduled rather than an outcome already demonstrated through completed testing volumes.

The announcement focused on access and readiness. It did not quantify initial patient demand, nationwide utilisation or revenue already generated by the broader rollout.

Training Prepares Teams for Clinician Engagement

Field sales staff completed training in both tests, their intended clinical uses and the processes needed to access them. This prepared teams to discuss the products with general practitioners and relevant specialists.

Joint sales and marketing plans had also been agreed. Their stated purpose was to build awareness, provide clinician education and support appropriate referrals, rather than replace the clinical assessment involved in ordering tests.

The national distribution partner would contribute its collection infrastructure and clinician relationships. Proteomics International retained its specialist laboratory responsibilities, creating separate operational roles within the wider access model.

Collection and Payment Systems Form the Next Step

Systems and process integration were scheduled to go live on 26 October. From that date, participating collection centres were expected to accept patients for blood collection and process payments.

The tests would initially be offered on a private-pay basis. Previously announced Australian patient prices were AUD 495 for Promarker D and AUD 997 for Promarker Eso.

Those amounts were patient prices rather than a statement of the company's net revenue per test. The announcement did not disclose national sales volumes or a forecast derived from multiplying those prices by expected utilisation.

Laboratory Responsibilities Remain with the Developer

Proteomics International would continue performing laboratory testing at its accredited facility. It would also provide clinical reporting, scientific and medical support, and quality and regulatory compliance.

The distribution partner's responsibilities covered specimen collection, pathology distribution and clinician engagement. This division allowed broader collection access while retaining the testing and reporting function within the company's specialist operation.

Completing integration and supporting clinicians were immediate priorities. The update described the planned operating pathway, without representing operational readiness alone as proof of commercial uptake.

Endo Preparation Follows the Same Access Framework

The company had announced completion of model refinement and independent validation for Promarker Endo, its endometriosis blood test. Commercial availability was expected during Q3FY27, covering January to March 2027.

That timing remained subject to clinical deployment and applicable quality, accreditation and regulatory requirements. Systems, collection processes and clinician relationships established through the first two tests were expected to support the later introduction.

The portfolio remained at an early commercialisation stage, and the company stated that revenue under the distribution agreement could not yet be reliably estimated. Implementation timing, clinician adoption, patient utilisation and applicable requirements therefore remained relevant to the progression from planned availability to revenue.